25.60
+5.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SI-BONE
From its filings with the US Securities and Exchange Commission
SI-BONE is based in San Jose, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SIBN. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $200.9m and a net loss of $18.9m. At that date it held total assets of $238.6m and shareholders' equity of $177.5m. By region, United States accounted for 95.1%, followed by International at 4.9%.
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum. With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma.
We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force, sales agents and resellers in other countries. As of December 31, 2025, over 140,000 procedures have been performed using our products since we introduced iFuse in 2009.
Our products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Since launching our first generation iFuse in 2009, we have launched multiple implant product lines, including iFuse 3D in 2017, iFuse TORQ in 2021, iFuse Bedrock Granite in 2022, and iFuse INTRA and iFuse TORQ TNT in 2024. In the United States, iFuse, iFuse 3D, iFuse TORQ and iFuse Bedrock Granite have clearances for applications in sacroiliac joint dysfunction, adult spinal deformity and pelvic trauma. iFuse TORQ TNT has clearances for applications in pelvic trauma and sacroiliac joint dysfunction.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 17 Oct 2018
- Employees
- 376
- Website
- si-bone.com ↗
- Head office
- 88 W. PLUMERIA DRIVE, SAN JOSE, CA, 95134
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Jeffrey DunnNon-Executive Chairman of the Board, since 2008$199,712
- Ms. Laura FrancisChief Executive Officer, Director, since 2015$7.1m
- Mr. Anshul MaheshwariChief Financial Officer$2.5m
- Mr. Anthony RecuperoPresident - Commercial Operations$2.6m
- Mr. Michael PisetskySecretary, Chief Business & Legal Affairs Officer
- Mr. Timothy DavisLead Independent Director$184,712
- Dr. John FreundIndependent Director$162,462
- Ms. Jeryl HillemanIndependent Director$179,712
- Mr. Gregory HinckleyIndependent Director$163,962
- Ms. Mika NishimuraIndependent Director$163,212
- Mr. Thomas WestIndependent Director$254,571
- Mr. Daniel WolfIndependent Director$262,485
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 31
- Social
- 86
- Governance
- 32
- Women in the workforce
- 43%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SI-BONE Inc possesses advanced proprietary technology, allowing it to develop innovative medical solutions for patients suffering from various spinal disorders.
- SI-BONE Inc has gained a strong reputation within the healthcare industry for its effective diagnostic and treatment solutions, resulting in increased trust from healthcare professionals and patients.
- SI-BONE Inc has a substantial portfolio of intellectual property rights, including patents and trademarks, providing a competitive advantage and protecting its innovative technologies.
Weaknesses
- SI-BONE Inc heavily relies on its primary product offerings, potentially exposing the company to market fluctuations and limited revenue streams.
- Compared to some major competitors, SI-BONE Inc has a relatively smaller market presence, which may limit its ability to reach a wider customer base and compete for market share.
- SI-BONE Inc's pricing structure may be perceived as higher compared to some alternatives in the market, potentially leading to pricing sensitivity among cost-conscious customers.
Opportunities
- SI-BONE Inc can explore opportunities to expand its reach into untapped geographical markets, allowing the company to target a wider customer base and increase its revenue potential.
- By continuously investing in research and development, SI-BONE Inc can introduce new products or enhancements to its existing product line, catering to evolving customer needs and expanding its market share.
- SI-BONE Inc can establish strategic partnerships with other companies or healthcare organizations to leverage complementary expertise and resources, fueling growth and market penetration.
Threats
- SI-BONE Inc operates in a highly competitive industry, facing competition from both established companies and emerging startups, which could impact its market share and profitability.
- The medical industry is subject to stringent regulations and compliance requirements. SI-BONE Inc may face challenges related to regulatory approvals, affecting its ability to commercialize products in a timely manner.
- Fluctuations in the global economy, changes in healthcare policies, or economic downturns can influence customer spending patterns, potentially impacting SI-BONE Inc's revenues and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.